The VEGF/VEGFR axis revisited: implications for cancer therapy

P Mabeta, V Steenkamp - International journal of molecular sciences, 2022 - mdpi.com
The vascular endothelial growth factor (VEGF)/vascular endothelial growth factor receptor
(VEGFR) axis is indispensable in the process of angiogenesis and has been implicated as a …

Epithelial specific splicing regulator proteins as emerging oncogenes in aggressive prostate cancer

R Advani, S Luzzi, E Scott, C Dalgliesh… - Oncogene, 2023 - nature.com
Prostate cancer progression is connected to the activity of conventional oncogenes and
tumour suppressors and driven by circulating steroid hormones. A key issue has been how …

Cohesin regulates alternative splicing

AK Singh, Q Chen, C Nguyen, D Meerzaman… - Science …, 2023 - science.org
Cohesin, a trimeric complex that establishes sister chromatid cohesion, has additional roles
in chromatin organization and transcription. We report that among those roles is the …

The calcium channel TRPC6 promotes chemotherapy-induced persistence by regulating integrin α6 mRNA splicing

D Mukhopadhyay, HL Goel, C Xiong, S Goel, A Kumar… - Cell reports, 2023 - cell.com
Understanding the cell biological mechanisms that enable tumor cells to persist after therapy
is necessary to improve the treatment of recurrent disease. Here, we demonstrate that …

MicroRNA and alternative mRNA splicing events in cancer drug response/resistance: potent therapeutic targets

R Marima, FZ Francies, R Hull, T Molefi, M Oyomno… - Biomedicines, 2021 - mdpi.com
Cancer is a multifaceted disease that involves several molecular mechanisms including
changes in gene expression. Two important processes altered in cancer that lead to …

Small non-coding RNAs and pancreatic ductal adenocarcinoma: Linking diagnosis, pathogenesis, drug resistance, and therapeutic potential

RN Fuller, A Morcos, JG Bustillos, DC Molina… - … et Biophysica Acta (BBA …, 2024 - Elsevier
This review comprehensively investigates the intricate interplay between small non-coding
RNAs (sncRNAs) and pancreatic ductal adenocarcinoma (PDAC), a devastating malignancy …

[HTML][HTML] Impact of alternative splicing on mechanisms of resistance to anticancer drugs

M Reviejo, M Soto, E Lozano, M Asensio… - Biochemical …, 2021 - Elsevier
A shared characteristic of many tumors is the lack of response to anticancer drugs. Multiple
mechanisms of pharmacoresistance (MPRs) are involved in permitting cancer cells to …

The eukaryotic translation initiation factor eIF4E reprograms alternative splicing

M Ghram, G Morris, B Culjkovic‐Kraljacic… - The EMBO …, 2023 - embopress.org
Aberrant splicing is typically attributed to splice‐factor (SF) mutation and contributes to
malignancies including acute myeloid leukemia (AML). Here, we discovered a mutation …

An intricate rewiring of cancer metabolism via alternative splicing

G Temaj, S Chichiarelli, S Saha… - Biochemical …, 2023 - Elsevier
All human genes undergo alternative splicing leading to the diversity of the proteins.
However, in some cases, abnormal regulation of alternative splicing can result in diseases …

Overcoming cancer drug-resistance calls for novel strategies targeting abnormal alternative splicing

J Zhang, X Xu, H Deng, L Liu, Y Xiang… - Pharmacology & …, 2024 - Elsevier
Abnormal gene alternative splicing (AS) events are strongly associated with cancer
progression. Here, we summarize AS events that contribute to the development of drug …